Stephen David Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephen David Robinson has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Georgios Giamas
International Oncology Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Oncology Department of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
6 shared publications - Giles Critchley
Department of Neurosurgery, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
6 shared publications - Sarah Kingdon
Tessa Jowell Brain Cancer Mission, London, UK
4 shared publications - Bilal A. Tahir
Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK
3 shared publications - Ciaran Scott Hill
National Hospital for Neurology and Neurosurgery, Brain Tumour Service (Neuro-Oncology), London, UK
3 shared publications - Edward Chandy
Sussex Cancer Centre, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
3 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 178 (2) , 41
Report of treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification
Purpose: Glioblastoma is the most common primary brain cancer in adults, with half of cases diagnosed in patients aged ≥ 65 years. However, definitions of older adults vary, resulting in treatment variation between centres. This study aimed to report on the treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification. Methods: We conducted a retrospective, multicentre cohort study (Histo-Mol GBM Collaborative) of consecutive patients with pathologically confirmed glioblastoma, IDH-wildtype diagnosed in 2021, according to the 2021 WHO CNS 5 classification, across 52 centres in the UK, Ireland, New Zealand, and Australia. Demographic, molecular, treatment, and survival data were analysed. Results: Of 1,857 patients, 863 (46.5%) were aged ≥ 65 years. Older patients had worse performance status, were more likely to have a biopsy, and received less intensive oncological therapy. Molecular testing was less comprehensive for older patients, but in those patients tested there was no difference with older age. Median overall survival declined with older age, with the steepest reduction in patients ≥ 70 years. Patients aged 65–69 derived comparable benefit from conventionally fractionated chemoradiation to adults aged < 65, whereas outcomes in those aged ≥ 70 were equivalent when treated with hypofractionated or conventionally fractionated chemoradiation. In multivariate analysis, oncological treatment intensity, completion of adjuvant therapy, and MGMT promoter methylation were independent predictors of survival. Conclusions: This international clinical dataset of adults diagnosed with glioblastoma since the introduction of the WHO CNS 5 criteria supports the use of conventionally fractionated chemoradiation in fit patients < 70, while hypofractionated regimens are appropriate for those ≥ 70. Surgical extent, treatment intensity, and MGMT methylation remain key determinants of survival in older patients with glioblastoma.
- 4 June 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 178 (2) , 41
Open AccessReport of treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification
Purpose: Glioblastoma is the most common primary brain cancer in adults, with half of cases diagnosed in patients aged ≥ 65 years. However, definitions of older adults vary, resulting in treatment variation between centres. This study aimed to report on the treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification. Methods: We conducted a retrospective, multicentre cohort study (Histo-Mol GBM Collaborative) of consecutive patients with pathologically confirmed glioblastoma, IDH-wildtype diagnosed in 2021, according to the 2021 WHO CNS 5 classification, across 52 centres in the UK, Ireland, New Zealand, and Australia. Demographic, molecular, treatment, and survival data were analysed. Results: Of 1,857 patients, 863 (46.5%) were aged ≥ 65 years. Older patients had worse performance status, were more likely to have a biopsy, and received less intensive oncological therapy. Molecular testing was less comprehensive for older patients, but in those patients tested there was no difference with older age. Median overall survival declined with older age, with the steepest reduction in patients ≥ 70 years. Patients aged 65–69 derived comparable benefit from conventionally fractionated chemoradiation to adults aged < 65, whereas outcomes in those aged ≥ 70 were equivalent when treated with hypofractionated or conventionally fractionated chemoradiation. In multivariate analysis, oncological treatment intensity, completion of adjuvant therapy, and MGMT promoter methylation were independent predictors of survival. Conclusions: This international clinical dataset of adults diagnosed with glioblastoma since the introduction of the WHO CNS 5 criteria supports the use of conventionally fractionated chemoradiation in fit patients < 70, while hypofractionated regimens are appropriate for those ≥ 70. Surgical extent, treatment intensity, and MGMT methylation remain key determinants of survival in older patients with glioblastoma.
- Open Access
- 17 April 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (5) , 102744
Combined multi-omics and multi-spectral profiling of plasma extracellular vesicles reveals liquid biopsy biomarkers for glioma diagnosis
- 17 April 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (5) , 102744
Open AccessCombined multi-omics and multi-spectral profiling of plasma extracellular vesicles reveals liquid biopsy biomarkers for glioma diagnosis
- Open Access
- 8 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (2) , 157
Understanding the difference in symptoms and outcomes between glioblastoma patients diagnosed based on histological or molecular criteria: a retrospective cohort analysis from the Histo-Mol GBM collaborative
Purpose: Since the 2021 World Health Organisation (WHO) classification, glioblastoma could be diagnosed based on classical histological features (hGBM) or molecular criteria (mGBM). However, prior studies included patients who required reclassification as a mGBM, potentially biasing survival analyses. The Histo-Mol GBM collaborative performed an international multicentre retrospective real-world cohort study of glioblastoma patients diagnosed according to WHO CNS 5. Methods: We identified consecutive patients diagnosed in 2021 with IDH wildtype glioblastoma according to WHO CNS 5. Clinicopathological, treatment, and survival data were collected and compared between mGBM and hGBM. Results: 1828 patients diagnosed with glioblastoma were included. 75 mGBM patients (8.4% of tested patients) were identified, with no difference in age (median 61 vs 64, p = 0.057), gender ( p = 0.937), or proportion with performance status 0–1 (82.7% vs 68.3%, p = 0.052) compared to hGBM. mGBM patients had an extended interval from MRI to surgery (median 23 vs 14 days, p < 0.001) and more frequently underwent biopsy (69.3% vs 30.3%, p < 0.001), but equivalent proportions received oncological treatment (80.0% vs 78.7%, p = 0.784). Overall survival (OS) from surgery was not different ( p = 0.063). However, OS from initial MRI, stratified by surgical extent, demonstrated improved OS for mGBM patients (hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.43–0.73). Propensity score matching identified improved survival following resection (HR 0.48, 95% CI: 0.24–0.95; median OS: 26.0 versus 14.0 months, p = 0.031) but not biopsy (HR 1.10, 95% CI: 0.71–1.72). Conclusion: In this large real-world cohort, mGBMs had longer OS than hGBMs following resection with implications for prognostication and clinical decision making.
- 8 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (2) , 157
Open AccessUnderstanding the difference in symptoms and outcomes between glioblastoma patients diagnosed based on histological or molecular criteria: a retrospective cohort analysis from the Histo-Mol GBM collaborative
Purpose: Since the 2021 World Health Organisation (WHO) classification, glioblastoma could be diagnosed based on classical histological features (hGBM) or molecular criteria (mGBM). However, prior studies included patients who required reclassification as a mGBM, potentially biasing survival analyses. The Histo-Mol GBM collaborative performed an international multicentre retrospective real-world cohort study of glioblastoma patients diagnosed according to WHO CNS 5. Methods: We identified consecutive patients diagnosed in 2021 with IDH wildtype glioblastoma according to WHO CNS 5. Clinicopathological, treatment, and survival data were collected and compared between mGBM and hGBM. Results: 1828 patients diagnosed with glioblastoma were included. 75 mGBM patients (8.4% of tested patients) were identified, with no difference in age (median 61 vs 64, p = 0.057), gender ( p = 0.937), or proportion with performance status 0–1 (82.7% vs 68.3%, p = 0.052) compared to hGBM. mGBM patients had an extended interval from MRI to surgery (median 23 vs 14 days, p < 0.001) and more frequently underwent biopsy (69.3% vs 30.3%, p < 0.001), but equivalent proportions received oncological treatment (80.0% vs 78.7%, p = 0.784). Overall survival (OS) from surgery was not different ( p = 0.063). However, OS from initial MRI, stratified by surgical extent, demonstrated improved OS for mGBM patients (hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.43–0.73). Propensity score matching identified improved survival following resection (HR 0.48, 95% CI: 0.24–0.95; median OS: 26.0 versus 14.0 months, p = 0.031) but not biopsy (HR 1.10, 95% CI: 0.71–1.72). Conclusion: In this large real-world cohort, mGBMs had longer OS than hGBMs following resection with implications for prognostication and clinical decision making.
- 12 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 104000
Access to Stereotactic Radiosurgery Centres Across the United Kingdom—An Investigation of Travel Time
- 12 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 104000
Access to Stereotactic Radiosurgery Centres Across the United Kingdom—An Investigation of Travel Time
- Open Access
- 10 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 49, 103996
Defining the Clinical Target Volume in Postoperative Thymic Epithelial Tumours - A Clinical Practice Guide for UK Clinical Oncologists
- 10 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 49, 103996
Open AccessDefining the Clinical Target Volume in Postoperative Thymic Epithelial Tumours - A Clinical Practice Guide for UK Clinical Oncologists
- Open Access
- 6 November 2025
- Published by Springer Nature in Research Square
Understanding the difference in symptoms and outcomes between glioblastoma patients diagnosed based on histological or molecular criteria: a retrospective cohort analysis from the Histo-Mol GBM collaborative
Purpose: Since the 2021 World Health Organisation (WHO) classification, glioblastoma could be diagnosed based on classical histological features (hGBM) or molecular criteria (mGBM). However, prior studies included patients who required reclassification as a mGBM, potentially biasing survival analyses. The Histo-Mol GBM collaborative performed an international multicentre retrospective real-world cohort study of glioblastoma patients diagnosed according to WHO CNS 5. Methods: We identified consecutive patients diagnosed in 2021 with IDH wildtype glioblastoma according to WHO CNS 5. Clinicopathological, treatment, and survival data were collected and compared between mGBM and hGBM. Results: 1828 patients diagnosed with glioblastoma were included. 75 mGBM patients (8.4% of tested patients) were identified, with no difference in age (median 61 vs 64, p=0.057), gender (p=0.937), or proportion with performance status 0-1 (82.7% vs 68.3%, p=0.052) compared to hGBM. mGBM patients had an extended interval from MRI to surgery (median 23 vs 14 days, p<0.001) and more frequently underwent biopsy (69.3% vs 30.3%, p<0.001), but equivalent proportions received oncological treatment (80.0% vs 78.7%, p=0.784). Overall survival (OS) from surgery was not different (p=0.063). However, OS from initial MRI, stratified by surgical extent, demonstrated improved OS for mGBM patients (hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.43-0.73). Propensity score matching identified improved survival following resection (HR 0.48, 95% CI: 0.24-0.95; median OS: 26.0 versus 14.0 months, p=0.031) but not biopsy (HR 1.10, 95% CI: 0.71-1.72). Conclusion: In this large real-world cohort, mGBMs had longer OS than hGBMs following resection with implications for prognostication and clinical decision making.
- 6 November 2025
- Published by Springer Nature in Research Square
Open AccessUnderstanding the difference in symptoms and outcomes between glioblastoma patients diagnosed based on histological or molecular criteria: a retrospective cohort analysis from the Histo-Mol GBM collaborative
Purpose: Since the 2021 World Health Organisation (WHO) classification, glioblastoma could be diagnosed based on classical histological features (hGBM) or molecular criteria (mGBM). However, prior studies included patients who required reclassification as a mGBM, potentially biasing survival analyses. The Histo-Mol GBM collaborative performed an international multicentre retrospective real-world cohort study of glioblastoma patients diagnosed according to WHO CNS 5. Methods: We identified consecutive patients diagnosed in 2021 with IDH wildtype glioblastoma according to WHO CNS 5. Clinicopathological, treatment, and survival data were collected and compared between mGBM and hGBM. Results: 1828 patients diagnosed with glioblastoma were included. 75 mGBM patients (8.4% of tested patients) were identified, with no difference in age (median 61 vs 64, p=0.057), gender (p=0.937), or proportion with performance status 0-1 (82.7% vs 68.3%, p=0.052) compared to hGBM. mGBM patients had an extended interval from MRI to surgery (median 23 vs 14 days, p<0.001) and more frequently underwent biopsy (69.3% vs 30.3%, p<0.001), but equivalent proportions received oncological treatment (80.0% vs 78.7%, p=0.784). Overall survival (OS) from surgery was not different (p=0.063). However, OS from initial MRI, stratified by surgical extent, demonstrated improved OS for mGBM patients (hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.43-0.73). Propensity score matching identified improved survival following resection (HR 0.48, 95% CI: 0.24-0.95; median OS: 26.0 versus 14.0 months, p=0.031) but not biopsy (HR 1.10, 95% CI: 0.71-1.72). Conclusion: In this large real-world cohort, mGBMs had longer OS than hGBMs following resection with implications for prognostication and clinical decision making.
- Open Access
- 10 June 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (6) , 441-457
A Review of Focal Therapies for Small Cell Lung Cancer Brain Metastases
- 10 June 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (6) , 441-457
Open AccessA Review of Focal Therapies for Small Cell Lung Cancer Brain Metastases
- Open Access
- 10 February 2025
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 31 (9) , 846-859
Spatial biology – unravelling complexity within the glioblastoma microenvironment
- 10 February 2025
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 31 (9) , 846-859
Open AccessSpatial biology – unravelling complexity within the glioblastoma microenvironment
- Open Access
- 1 July 2024
- Published by Springer Nature in BMC Methods
- Vol. 1 (1) , 1-17
Confirming size-exclusion chromatography as a clinically relevant extracellular vesicles separation method from 1mL plasma through a comprehensive comparison of methods
Background: Extracellular vesicles (EVs) are amongst the most promising candidates for developing blood-based biomarkers. However, patient sample availability is a key barrier to translational research whilst most biobanks store samples of 1.5mL volume or less. To date, there is no consensus on the most suitable method of EV separation and current techniques frequently require large volumes of biofluids, complicated technology, technical expertise, or significant operating costs, which prevents their widespread adoption by less EV-focussed laboratories. Therefore, there is a need for an easy and reproducible method that separates representative EVs from clinically relevant 1mL volumes of plasma prior to subsequent biomarker identification. Methods: In this study, EVs were separated from a clinically relevant 1mL volume of human plasma using four different separation techniques: size exclusion chromatography (SEC), differential ultracentrifugation, precipitation, and immunoaffinity magnetic bead capture. The EVs were characterised using several orthogonal techniques (protein quantification, nanoparticle tracking analysis, transmission electron microscopy, Western blot, single particle interferometric reflectance imaging sensing, and mass spectrometry-based proteomics) to comprehensively compare the separated samples. Results: We provide examples of anticipated results highlighting that SEC-processed samples have greater protein quantification yield, greater particle yield of the expected size for EVs, and sufficient EV purity, which facilitates effective EV cargo assessment by proteomics. Moreover, we confirm significant overlap with known EV-related proteins within the Vesiclepedia database. Additionally, using single particle interferometric reflectance imaging sensing (Leprechaun®), we identify that SEC has the most representative surface tetraspanin distribution of the separated EV population compared to unprocessed plasma. Discussion: Given that SEC requires minimal expertise, no complicated technology and can separate EVs within 90 min, this comparison reinforces SEC as a clinically relevant EV separation method from 1mL of plasma making it suitable for widespread implementation.
- 1 July 2024
- Published by Springer Nature in BMC Methods
- Vol. 1 (1) , 1-17
Open AccessConfirming size-exclusion chromatography as a clinically relevant extracellular vesicles separation method from 1mL plasma through a comprehensive comparison of methods
Background: Extracellular vesicles (EVs) are amongst the most promising candidates for developing blood-based biomarkers. However, patient sample availability is a key barrier to translational research whilst most biobanks store samples of 1.5mL volume or less. To date, there is no consensus on the most suitable method of EV separation and current techniques frequently require large volumes of biofluids, complicated technology, technical expertise, or significant operating costs, which prevents their widespread adoption by less EV-focussed laboratories. Therefore, there is a need for an easy and reproducible method that separates representative EVs from clinically relevant 1mL volumes of plasma prior to subsequent biomarker identification. Methods: In this study, EVs were separated from a clinically relevant 1mL volume of human plasma using four different separation techniques: size exclusion chromatography (SEC), differential ultracentrifugation, precipitation, and immunoaffinity magnetic bead capture. The EVs were characterised using several orthogonal techniques (protein quantification, nanoparticle tracking analysis, transmission electron microscopy, Western blot, single particle interferometric reflectance imaging sensing, and mass spectrometry-based proteomics) to comprehensively compare the separated samples. Results: We provide examples of anticipated results highlighting that SEC-processed samples have greater protein quantification yield, greater particle yield of the expected size for EVs, and sufficient EV purity, which facilitates effective EV cargo assessment by proteomics. Moreover, we confirm significant overlap with known EV-related proteins within the Vesiclepedia database. Additionally, using single particle interferometric reflectance imaging sensing (Leprechaun®), we identify that SEC has the most representative surface tetraspanin distribution of the separated EV population compared to unprocessed plasma. Discussion: Given that SEC requires minimal expertise, no complicated technology and can separate EVs within 90 min, this comparison reinforces SEC as a clinically relevant EV separation method from 1mL of plasma making it suitable for widespread implementation.
- 13 May 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (9) , e301-e311
Management Approaches in WHO Grade III Meningioma: A National Oncology Trainees' Collaborative for Healthcare Research (NOTCH) UK Multi-Centre Retrospective Study
- 13 May 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (9) , e301-e311
Management Approaches in WHO Grade III Meningioma: A National Oncology Trainees' Collaborative for Healthcare Research (NOTCH) UK Multi-Centre Retrospective Study